VIRI News and Press, Virios Therapeutics Inc. From 01/26/22

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, ...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that Greg Duncan, Chairman and Chief Executive Officer, will p...

New Potential Treatment Targets Millions of Fibromyalgia Patients Worldwide First Ever FDA “Fast Track” Designation for Fibromyalgia Development Candidate Phase 2b Clinical Trial Builds on Positive Phase 2a Data Virios Therapeutics, Inc. ...

Virios Therapeutics, Inc. (VIRI) Q3 2021 Earnings Conference Call November 11, 2021, 08:30 AM ET Company Participants Angela Walsh - SVP of Finance, Secretary & Treasurer Greg Duncan - CEO & Chairman Conference Call Participants David Bautz - Zacks Small Research Presentation Operator...

Virios Therapeutics (NASDAQ:VIRI): Q3 GAAP EPS of -$0.49 beats by $0.21. As of September 30, 2021, cash totaled $19.2M. The Company believes it will have sufficient resources to fund planned operations into Q1 2023. Press Release For further details see: Virios Therapeutics EPS beats by...

Over 200 patients Enrolled in Fibromyalgia Phase 2b Trial Filed Investigational New Drug Application with FDA to Assess IMC-1 Potential to Treat Irritable Bowel Syndrome Cash Position Supports Operations into Q1 2023 Management to Host Webcast and Conference ...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that its third quarter 2021 financial results will be reported on Thursday, Nov...

Intellectual Property Estate Now Includes Valacyclovir-Celecoxib Combination Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, anno...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company ov...

The following slide deck was published by Virios Therapeutics, Inc. in conjunction with this event. For further details see: Virios Therapeutics (VIRI) Investor Presentation - Slideshow